In a victory for Gilead, Brazilian antitrust authorities dismissed a complaint alleging the company charged “abusive” prices for a hepatitis C treatment.
News
STAT+: ASCO showcased the payoff for new cancer medicines: longer lives
As new cancer drugs arrive, regulators and doctors still struggle with when to use drugs based on earlier data and when to wait for survival data. #ASCO23 […]
News
STAT+: As Ginkgo stock sinks, CEO Jason Kelly tries to win over drugmakers in San Francisco
Ginkgo, a company that said its engineered cells could help make almost anything, is trying to drum up business. […]
News
STAT+: After four years of big talk, mega startup Sana prepares to deliver some data
“I had this kind of naive view that if you start with the same cell every time, and you run the same process, every time, then you’re going to end… […]
